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Abstract – Gla ¨sser’s disease is a re-emerging swine disease characterized by a severe septicaemia.
Vaccination has been widely used to control the disease, although there is a lack of extended cross-
protection. Trimeric autotransporters, a family of surface exposed proteins implicated in host-pathogen
interactions, are good vaccine candidates. Members of this family have been described in Haemophilus
parasuis and designated as virulence-associated trimeric autotransporters (VtaA). In this work, we produced
15 recombinant VtaA passenger domains and looked for the presence of antibodies directed against them in
immune sera by immunoblotting. After infection with a subclinical dose of H. parasuis Nagasaki, an IgG
mediated antibody response against 6 (VtaA1, 5, 6, 8, 9 and 10) of the 13 VtaA of the Nagasaki strain was
detected, indicating that they are expressed in vivo. IgA production against VtaA was detected in only one
animal. VtaA were more likely to be late antigens when compared to early (Omp P5 and Omp P6) and late
(YaeT) deﬁned antigens. Antibody cross-reaction with two orthologs of Nagasaki’s VtaA5 and 6, VtaA15
and 16 of strain HP1319, was also detected. No antibodies against VtaAwere detected in the sera of animals
immunized with a bacterin of the Nagasaki strain, suggesting poor expression in the in vitro conditions
used. Taken together, these results indicate that VtaA are good candidate immunogens that could be used to
improve H. parasuis vaccines. However, their capacity to confer protective immunity needs to be further
studied.
Haemophilus parasuis / VtaA / OMP / antibody / cross-reactivity
1. INTRODUCTION
Haemophilus parasuis is a small, pleomor-
phic, NAD-dependent member of the family
Pasteurellaceae.Thisbacteriumistheetiological
agent of Gla ¨sser’s disease in swine, which is
characterizedbypolyserositisandarthritis. Once
a sporadic disease, it has increased in preva-
lence and severity in recent years with the adop-
tion of new production technologies which has
led to pigs being susceptible to this infection
[26]. The immune status of a herd is an impor-
tant determinant for the outcome of the disease,
and since the 1980s, reports on the use of
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have been published [27, 30]. However, a lack
of protective cross-immunity against some
strains and partial cross-protection among sero-
types has been reported [20, 24], pointing to the
difﬁculty in identifying protective immunogens
for a universal vaccine. Initial studies have
already shown the importance of circulating
antibodies in controlling H. parasuis infection
[20, 24]. After experimental infection in swine,
production of antibodies against outer mem-
brane proteins (OMP) has been described
[15, 21]. The production of swine antibodies
against speciﬁc H. parasuis proteins has been
studied and FhuA, OmpA, PalA, Omp2, D15
and HPS06257 have been described as anti-
genic proteins [7, 33, 34].
The trimeric autotransporter (AT-2) protein
family members are characterized by a mosaic
structure formed by a translocator domain that
anchors the protein to the membrane and allows
cell-surface exposure of the functional passen-
ger domain, which is divided into stalk, connec-
tor, and head segments [31]. AT-2 enable
high-afﬁnity multivalent adhesive interactions
with host cells and extracellular matrix compo-
nents [6, 9, 28]. Some can inhibit phagocyto-
sis or complement-mediated killing, helping
the bacteria to overcome the innate immune
response [12, 29]. In animal models, the protec-
tive capacities of AT-2 have been explored by
both passive transfer of antibodies and by chal-
lenging animals immunized with recombinant
AT-2 [1, 8, 16]. The existence of virulence-
associated trimeric autotransporters (VtaA) in
H. parasuis has been recently reported [25].
In tissue-invasive H. parasuis strains, they con-
stitute a multigene family of at least 10 copies
per genome, which can be subdivided into three
groupsonthebasisofsequencesimilaritiesofthe
translocator domains. Interestingly, the group 1
variant is associated to pathogenic strains but
not to H. parasuis non-invasive strains [25].
The objective of this study was to investi-
gate the antigenicity of VtaA molecules
expressed during an experimental infection
with H. parasuis Nagasaki. All 13 VtaA pas-
senger domains of the homologous Nagasaki
strain, produced as recombinant proteins, were
assayed and antibody cross-reaction was
assessed with two other VtaA from a heterolo-
gous non-serotypeable strain, HP1319.
2. MATERIALS AND METHODS
2.1. Culture and bacterin production
After an in vivo passage, the highly virulent [26]
H. parasuis strain Nagasaki was plated onto choco-
late agar and incubated at 37  Ci na na t m o s p h e r e
of 5% CO2. Bacterial growth was harvested at 18 h
post-inoculation and suspended in sterile PBS.
AO D 600 = 0.2 bacterial suspension (equivalent to
approximately 10
8 CFU/mL) was made followed
by two 10-fold dilutions to adjust the bacterial con-
centration to   10
6 CFU/mL. The number of colony
forming units was determined after 48 h incubation
by plating 10-fold dilutions on chocolate agar plates.
The bacterin used in this study was prepared by cen-
trifuging an H. parasuis bacterial suspension contain-
ing 10
9 CFU/mL, discarding the supernatant, and
resuspending the pellet in 0.2% formalin solution pre-
pared in PBS. This suspension was left at 4  Cf o r
72 h to achieve complete inactivation and was adju-
vanted using a water-in-oil emulsion (Laboratorios
HIPRA, Amer, Spain).
2.2. Experimental infection and immunization
All procedures involving animals followed EU
norms (Council Directive 86/609/EEC). To avoid
maternal antibody interference and colonization by
H. parasuis from the sows, snatch-farrowed colos-
trum-deprived pigs (Large white · Landgrace) were
used in this study [3]. The six animals used were
divided into two groups at 21 days after birth. The
ﬁrst group (animals 127, 131, 172 and 198) was
intranasally inoculated with a subclinical dose
(10
6 CFU/animal) of H. parasuis Nagasaki, whereas
the second group (animals 122 and 143) was intra-
muscularly vaccinated with a H. parasuis Nagasaki
bacterin (equivalent to 10
9 CFU/animal) and boosted
15 days later. Pre-immune sera were collected 7 days
pre-infection or pre-immunization and immune sera
were collected at 7, 14, 22, 27 and 42 days post-treat-
ment (infection or immunization). All pigs were
euthanized at 42 days post-treatment (dpt).
2.3. Recombinant expression of VtaA passenger
domains
The passenger domains, excluding the transloca-
tor domain and the extended signal peptide, of the
Vet. Res. (2010) 41:26 A. Olvera et al.
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(vtaA1t ovtaA13) and of the vtaA15 and vtaA16
genes of the heterologous serotype strain HP1319
were ampliﬁed with the primers listed in Table I
using previously described procedures [25]. Strain
HP1319 is a non-typable isolate from the meninges
of an animal suffering polyserositis. Additionally,
three fragments of the passenger domain of vtaA10
were ampliﬁed: a 30 fragment (C-terminal or stalk),
the central collagen repeats, and a 50 fragment
(N-terminal or head) (Tab. I). The ampliﬁed gene
fragments were cloned using the pASK-IBA33plus
plasmid system (IBA – BioTAGnologies, Go ¨ttingen,
Germany) and transformed in Escherichia coli
Rosetta(DE3)pLysS (Novagen – Merck Chemicals
Ltd., Nottingham, UK). One colony was inoculated
in 5 mL of LB broth containing carbenicillin
(50 lg/mL) and cloramphenicol (34 lg/mL), incu-
bated at 37  C (225 rpm) to an OD600 of 0.4–0.5,
and left overnight at 25  C without shaking. After
centrifugation, bacteria were used to inoculate
50 mL of the above mentioned media. Recombinant
protein production was induced for 2 h at 25  C
when the culture reached an OD600 of 0.4–0.6 by
adding 0.2 lg/mL of anhydrotetracycline (AHT).
When necessary, the peptides were puriﬁed using
the HisSpinTrap kit (GE Healthcare, Barcelona,
Spain) and quantiﬁed with the BCA protein assay
kit (Pierce-Thermo Scientiﬁc, Rockford, IL, USA)
according to the manufacturer’s instructions.
2.4. Immunoblotting of OMP from H. parasuis
The antibody response was evaluated by immu-
noblotting. Brieﬂy, bacterial cultures were grown
to OD600 = 0.7 in PPLO supplemented with 1% of
IsoVitaleX (BD, Madrid, Spain). OMP were puriﬁed
using the sodium N-lauroyl sarcosinate method [4]
and quantiﬁed with the EZQ protein quantiﬁcation
kit (Invitrogen, Barcelona, Spain). Twenty-ﬁve lg
of the individual OMP were suspended in 4· SDS
buffer, denaturated at 95  C for 15 min and sepa-
rated by molecular size in a NuPAGE
  Novex
4–12% Bis-Tris Gel (Invitrogen). Proteins were
transferred to a Hybond
TM ECL
TM nitrocellulose
membrane (GE Healthcare) by electrodiffusion. All
of the following steps were performed according
to the instructions provided in the ECL Advance
Western Blotting Detection Kit (GE Healthcare).
After blocking, the membranes were cut into strips,
incubated with different pig sera diluted 1:2000 in
blocking solution (GE Healthcare) for 1 h, and
washed with TBS-tween20. The presence of IgG
was detected by chemiluminescense with a mouse
anti-porcine IgG (AbD Serotec, Oxford, UK) conju-
gated with Horse Radish Peroxidase (HRP) diluted
1:250000. Imaging was performed with a Fluoro-
chem HD2 chemiluminescent workstation (Alpha
Innotech, San Leandro, CA, USA). To monitor the
maturation of the immune response, early antigens
Omp P5, Omp P6 and late antigen YeaT (also called
D15) [35] were identiﬁed in the OMP preparations
of the Nagasaki strain by MALDI-TOFF using
MASCOTT software analysis at the Institut de
Biotecnologia i de Biomedicina of the Universitat
Auto `noma de Barcelona.
2.5. Immunoblotting of recombinant VtaA
Recombinant E. coli pellets were solubilized by
adding 50 lL4 · SDS, Urea 8 M buffer pH = 7.6
(4% SDS, 8 M Urea, 0.2 M DTT, 10 mM NaHPO4,
60 mM NaCl, and 10 mM pefabloc) to a pellet from
a culture of OD600 = 1. The same buffer was used to
adjust the concentration of puriﬁed proteins to
0.3 lg/lL. These suspensions were denatured at
94  C for 15 min, 5 lL mixed with 5 lL of a loading
buffer (2· LDS (Invitrogen), 5% b-mercaptoethanol
and 1.2· SDS, Urea 2.4 M buffer) and incubated at
70  C for 10 min. The production of recombinant
protein was conﬁrmed in a NuPAGE
  Novex 4–12%
Bis-TrisGelgelstainedwithSYPROTangerine(Invit-
rogen). Immunoblotting was performed as described
above. For IgA detection an anti-porcine IgA conju-
gated with HRP diluted 1:100000 (AbD Serotec) was
used. Negative controls for immunoblotting assays
included pre-immune sera collected prior to infection
or vaccination and, for non-puriﬁed recombinant
VtaA, E. coli Rosetta(DE3)pLysS transformed with
an empty pASK-IBA33plus plasmid. As positive
controls, the 6· His C-terminal residues of the recom-
binantVtaAweredetectedusing an Anti-His(C-term)-
HRPAntibody (Invitrogen).
3. RESULTS
3.1. Kinetics of the antibody response against
whole OMP
Following H. parasuis infection or bacterin
immunization, all animals progressively devel-
opedaspeciﬁcIgGresponsevaryinginintensity
andinthenumberofdetectedOMPforeachindi-
vidual piglet (Fig. 1). By 42 dpt, all antiserum
recognized nearly the same antigenic repertoire.
Sera collected at 42 dpt from animals infected
with live bacteria (127, 131, 172 and 198)
vtaA antigenicity Vet. Res. (2010) 41:26
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ble, although they had different chemilumines-
cence intensities. No reactivity was detected
with the pre-immune sera (data not shown).
An immune response to early (Omp P5 and
Omp P6) and late (YaeT) antigens [35]w a s
identiﬁed (Fig. 1).
3.2. Antigenicity of the VtaA passenger domains
of the H. parasuis Nagasaki strain
None of the animals showed clinical signs
post-inoculation or post-vaccination. Since nor-
mal colonization of animals with E. coli is
unavoidable, immunoblot interpretation was
Table I. Primers used to amplify the vtaA passenger domains or fragments of the vtaA10 passenger domain.
The size of the ampliﬁed fragment (bp) isindicated in the ﬁrst column. All primers contained a restriction enzyme
BsaI target except for vtaA1w h i c hc o n t a i n e dar e s t r i c t i o ne n z y m eBsmBI target (underlined and in bold).
Gene Primer name Sequence
vtaA Haemophilus parasuis strain Nagasaki
vtaA1 (6 792 bp) adh7-bsm-L2(-)F ATGGTACGTCTCAAATGGCTGCATATCTTCAAGATGGTGC
adh7-bsm-30less ATGGTACGTCTCAGCGCTAACAATATCTCTTGATAATTGATTAAATC
vtaA2 (3 221 bp) adh3-L2(-)F ATGGTAGGTCTCAAATGGCTGCATATTTTCAAGATAGTTCTG
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA3 (3 138 bp) adh15-L2(-)F ATGGTAGGTCTCAAATGGCAGCATGGTTGGTAGATGGTTC
adh15-y(-)R ATGGTAGGTCTCAGCGCTAACAATATCTCTTGATAATTGATTAAATC
vtaA4 (3 095 bp) adh23-L2(-)F ATGGTAGGTCTCAAATGTCAGCTGCATATTTTGCAGGTGG
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA5 (2 720 bp) adh1/21-L2(-)F ATGGTAGGTCTCAAATGGGTGCACAACTTCACACAGGAAC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA6 (2 828 bp) adh19-L2(-)F ATGGTAGGTCTCAAATGTCAGCTACTCACTCAGGAACACC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA7 (2 618 bp) adh25-L2(-)F ATGGTAGGTCTCAAATGGCAGATCGTCATAAAGGAACTCC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA8 (2 756 bp) adh9-L2(-)F ATGGTAGGTCTCAAATGGCAAGGCTTTTTCTAGATGAGGC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA9 (2 405 bp) adh1/21-L2(-)F ATGGTAGGTCTCAAATGGGTGCACAACTTCACACAGGAAC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA10 (4 488 bp) adh11-L2(-)F ATGGTAGGTCTCAAATGGCATATCTTGAATATGGTGCTCGA
adh5-30less ATGGTAGGTCTCAGCGCTACGGTTGATCTTATTGTGAATATCG
vtaA11 (4 047 bp) adh5-L2(-)F ATGGTAGGTCTCAAATGTCAATTACTGATTCATCATATTTTCAAC
adh5-30less ATGGTAGGTCTCAGCGCTACGGTTGATCTTATTGTGAATATCG
vtaA12 (4 013 bp) adh17-L2(-)F ATGGTAGGTCTCAAATGGCAAGGCTTTTTCTAGATGGTGC
G3-30less ATGGTAGGTCTCAGCGCTTCTCTCTAACTTCGCACCCAATC
vtaA13 (3 752 bp) adh13-L2(-)F ATGGTAGGTCTCAAATGGCTAACACAACAAATACCGCAAAAC
G3-30less ATGGTAGGTCTCAGCGCTTCTCTCTAACTTCGCACCCAATC
vtaA10 Haemophilus parasuis strain Nagasaki partial constructions
vtaA10 50 (1 562 bp) adh11-L2(-)F ATGGTAGGTCTCAAATGGCATATCTTGAATATGGTGCTCGA
adh11parcial_50R ATGGTAGGTCTCAGCGCTCATAGCGGCAATCGTATCAATTTTA
vtaA10 central (1 004 bp) adh11parcial_CF ATGGTAGGTCTCAAATGGATAAAATTGATACGATTGCCGCTA
adh11parcial_CR ATGGTAGGTCTCAGCGCTTTTATCCGTTTGATTTTCGTCTTTCG
vtaA10 30 (1 980 bp) adh11parcial_30F ATGGTAGGTCTCAAATGGTTGGTCCGAAAGACGAAAATCAA
adh11parcial_30R ATGGTAGGTCTCAGCGCTACGGTTGATCTTATTGTGAATATCG
vtaA Haemophilus parasuis strain HP1319
vtaA15 (2 828 bp) adh19-L2(-)F ATGGTAGGTCTCAAATGTCAGCTACTCACTCAGGAACACC
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
vtaA16 (2 765 bp) adh9HP1319L2(-)F ATGGTAGGTCTCAAATGTCAGCTGCTGCTAACACAACAAAT
G1-30less ATGGTAGGTCTCAGCGCTACGACCAATATCTCTTGATAATTGAT
Vet. Res. (2010) 41:26 A. Olvera et al.
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noreactive proteins had similar molecular
weights. Therefore, recombinant VtaA5, VtaA9
and VtaA10 had to be puriﬁed. Speciﬁc porcine
IgG to 6 (VtaA1, 5, 6, 8, 9 and 10) of the 13
VtaA passenger domains of the Nagasaki strain
were detected in sera from piglets infected sub-
clinically (see Fig. 2 for an example). Multiple
banding was observed with the highest molecu-
lar weight VtaA, probably corresponding to
residual mutimeric forms of the native protein.
To monitor the appearance of antibodies dur-
ing the course of infection, sera collected at
different dpt were tested by immunoblotting.
The VtaA ﬁrst detected by IgG antibodies were
V t a A 5a n dV t a A 8( 2 2d p t ) ,f o l l o w e d5d a y s
later by VtaA6 and VtaA9. Finally, at the end
of the experiment (42 dpt), VtaA1 and VtaA10
were also revealed by sera from infected ani-
mals, although VtaA10 was detected only by
the sera of animal 172 (Fig. 3). The intensity
of the antibody response against VtaA increased
over time. IgA production was detected only at
42 dpt against one of the VtaA (VtaA10) and,
onlyinoneanimal(172)infectedwithasubclin-
ical dose (result not shown). No speciﬁc IgG or
IgA antibodies against the VtaA were detected
with pooled pre-immune sera of the 4 animals.
Sera from bacterin-immunized piglets were
consistentlynegative for VtaAduringthecourse
of the experiment despite a strong antibody
response against OMP (Fig. 1).
3.3. Antibody reactivity against the different
fragments of the VtaA10 passenger domain
VtaA10 fragments (stalk, collagen repeats
and head) were used to study antibody reactiv-
ity along VtaA structural domains, but they
also revealed their respective importance for
VtaA multimerization. After molecular size
separation by SDS-PAGE, the central collagen
repeats showed an apparent molecular weight
of 60 kDa instead of the expected 32 kDa
(Fig. 4). This reﬂected a strong interaction
between monomers. Similar ﬁndings were
observed with the stalk segment when the
SDS and urea concentrations were not sufﬁcient
Figure 1. Detection by immunoblot of IgG against OMP from the Nagasaki strain of H. parasuis. Sera
collected 22, 27 and 42 dpt from animals subclinically infected (127, 131, 172 and 198) or immunized with
a bacterin (122 and 143) were tested by immunoblotting with H. parasuis Nagasaki OMP. The positions of
two early antigens, Omp P5 and Omp P6, and a late antigen, YaeTare indicated. Molecular size standards in
kDa are shown on the left. C : Pooled pre-immune sera; * YaeT: Outer membrane protein assembly factor;
r Omp P5: Outer membrane protein P5; m Omp P6: Outer membrane protein P6.
vtaA antigenicity Vet. Res. (2010) 41:26
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Figure 2. Immunoblot screening for the presence of IgG toward recombinant VtaA passenger domains.
Sera from animals undergoing a subclinical infection (127, 131, 172 and 198) or bacterin immunization
(122, 143) at 42 dpt were tested by immunoblotting for the presence of speciﬁc IgG against VtaA passenger
domains; an example for each positive VtaA is given. The in silico calculated sizes of the Vta-reactive
material are indicated in column 1. Molecular weight standards are on the left of the ﬁgure. (A) For VtaA1,
VtaA6 and VtaA8 a lysate of recombinant E. coli Rosetta was used for the screening. An E. coli Rosetta
strain transformed with an empty plasmid was used as the negative control (C ). (B) For VtaA5, VtaA10
and VtaA9 puriﬁed proteins were used. Pre-immune sera were used as the negative control.
Vet. Res. (2010) 41:26 A. Olvera et al.
Page 6 of 11 (page number not for citation purpose)0
1
2
3
4
14 22 27 42
Days post-treatment
N
º
o
f
 
p
o
s
i
t
i
v
e
 
a
n
i
m
a
l
s
VtaA5
VtaA8
VtaA9
VtaA6
VtaA1
VtaA10
0
1
2
3
4
14 22 27 42
Days post-treatment
N
º
o
f
 
p
o
s
i
t
i
v
e
 
a
n
i
m
a
l
s
VtaA5
VtaA8
VtaA9
VtaA6
VtaA1
VtaA10
Figure 3. Kinetics of VtaA-speciﬁc IgG in H. parasuis infected piglets. The accumulated number of
animals (4 in total) producing speciﬁc IgG to VtaA at different dpt is presented. The ﬁgure summarizes all
results obtained by immunoblotting.
Repeats, motifs and  domains: Collagen HepHag HIM
Name Structure
Passenger (158 KDa)
Head (57 KDa)
Central (32 KDa)
Stalk (69 KDa)
SC HP S C H P
160 >
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60 >
50 >
Syprotangerine 172 42dpt
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٭
Figure 4. Detection and antigenic properties of three fragments of the VtaA10 passenger domain. The
stalk, collagen repeats and head of the entire VtaA10 passenger domain were produced in E. coli Rosetta.
Size separated proteins were detected by the Sypro tangerine stain. In a parallel SDS-PAGE, recombinant
proteins were immunodetected using a monoclonal antibody against the histidine C-terminal tails (aHis) of
the recombinant polypeptides or serum of animal 172 collected at 42 dpt. E. coli Rosetta transformed with
an empty pASK-IBA33 plasmid was used as a negative control (C ). Molecular size standards are shown
on the left of the ﬁgure. Arrows indicate weak speciﬁc bands for the head and multimeric stalk domains of
VtaA10. * Indicates multimeric and r monomeric forms of the stalk.
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(page number not for citation purpose) Page 7 of 11to disrupt entirely the multimeric structure of
this protein fragment. Aberrant protein tertiary
structure folding was further demonstrated by
the weak reactivity of the anti-histidine mono-
clonal antibody against the collagen domains
and stronger recognition of the multimeric stalk.
The head domain migrated at the expected rate
for a domain of this size with exposed histidine
tails. Using pig immune serum (animal 172 at
42 dpt) none of the three VtaA10 fragments
studied yielded a good antibody detection sig-
nal compared to the whole passenger domain,
although they were more efﬁciently produced
by the transformed E. coli. The central collagen
repeats were not detected while the multimeric
stalk and the head showed some reactivity with
immune sera 172 (42 dpt).
3.4. Antibody cross-reactivity
with VtaA from a heterologous strain
Pre-immune sera and sera at 42 dpt of the 4
animals (127, 131, 172 and 198) were used to
evaluate the degree of cross-reaction with puri-
ﬁed VtaA15 and VtaA16 (group 1 VtaA) pas-
senger domains belonging to strain HP1319.
PuriﬁedorthologsofVtaA15and16intheNaga-
sakistrain,VtaA6andVtaA8,wereusedasposi-
tive controls. Amino acid identities between
orthologs ranged between 72 and 95% for their
head while the stalks were more than 90% iden-
tical [25].Thenumberofcollagenrepeatsvaried
from two to four. Overall, the same IgG binding
patterns(andintensityofbinding)wereobtained
withtheheterologousandhomologousVtaA.No
reaction was detected with the corresponding
pre-immune sera (Fig. 5).
4. DISCUSSION
AT-2arethoughttobegooduniversalvaccine
candidates for the human pathogen serogroup
B meningococcus. They are surface exposed
moleculesthatparticipateinhost-pathogeninter-
actionsassociatedwithvirulence andcaninduce
a good antibody bactericidal response [2, 10].
The immune response against AT-2 has been
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Figure 5. Cross-reactivity of antibodies generated against VtaA of the H. parasuis Nagasaki strain with
orthologues of strain HP1319. Sera from animals undergoing a subclinical infection (127, 131, 172 and 198)
were used in immunoblotting experiments with recombinant VtaA15 and VtaA16 passenger domains
cloned from H. parasuis strain HP1319. All VtaA were puriﬁed, and 1.5 lg of each were used in the
immunoblots. Positive controls were VtaA6 and VtaA8 while the negative control was pooled pre-immune
sera. aHis: Monoclonal antibody against histidine C-terminal tails.
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models or convalescent sera; here we report the
antibodyresponseagainstAT-2afteracontrolled
exposure of a pathogen to its natural host.
Furthermore, VtaA are the ﬁrst AT-2 described
in H. parasuis [25] and their capacity to induce
a speciﬁc antibody response after an infection
with this bacterium will help understand host-
pathogen interactions in Gla ¨sser’s disease.
Sera from all pigs exposed to a subclinical
dose of H. parasuis recognized a similar OMP
antigenic repertoire, but to different degrees.
A genetic difference among animals is the most
likelyreasonforthisobservation.IgGantibodies
against VtaA were produced by animals inocu-
lated with live bacteria, but not by the piglets
immunized with a bacterin although they had
an efﬁcient qualitative and quantitative antibody
response against OMP. These results indicate
that VtaA are expressed in vivo, but not, or very
little, in the in vitro growth conditions used.
However, it can not be ruled out that they will
be expressed using other culture media or
growth conditions. Also, the results obtained
with bacterin-immunizedpiglets shouldbeinter-
preted carefully since only 2 animals were used,
and bacterial cultures for bacterin production
were grown in a different media than for OMP
puriﬁcation. Supporting these results, and in
agreementwiththeproteomemapofH.parasuis
strain SHO165 [35], our proteomic analysis of
high molecular weight OMP preparations from
the Nagasaki strain grown in vitro never
revealed VtaA. Furthermore, VtaA transcription
was detected in a study using samples from
necrotic swine lung, but not in several in vitro
studies using cultures mimicking the host condi-
tions [11, 18, 19].
Following inoculation of the Nagasaki
strain, IgG against VtaA started to be detected
at 22 dpt and, progressively, more VtaA were
detected. VtaA are more likely to be late anti-
gens when compared with well described early
(Omp P5 and Omp P6) and late antigens
(YaeT). This pattern of detection could be due
to a sequential expression of VtaA during the
course of infection together with the production
of antibodies speciﬁc for each VtaA. This could
be indicative of a surface antigen switching to
escape the host immune response. The lack of
antibodies against the remaining VtaA of viru-
lence-associated group 1 (VtaA2, VtaA3 and
VtaA7) and group 2 (VtaA11) pointed to the
existence of VtaA speciﬁc antibodies therefore
supporting this hypothesis. Also, no reactivity
was found with the more divergent passenger
domains of group 3 VtaA12 and VtaA13 [25].
Alternatively, the strong cross-reactivity with
VtaA15 and VtaA16, the orthologues of
Nagasaki VtaA5 and VtaA6, strongly suggests
the presence of some shared epitopes among
group 1 VtaA. This would indicate that only a
limited number of VtaA are expressed and the
maturation of the immune response is progres-
sively driven toward epitopes common to dif-
ferent VtaA. The relationship between amino
acid sequence variability and cross-reactivity
is of special interest for AT-2 based vaccines
in order to elucidate the VtaA repertoire neces-
sary to induce good protection.
Immunoblots of the head, the collagen
repeats and the stalk fragments of VtaA10 were
weakly antigenic compared to the whole pas-
senger domain. The need for the whole passen-
ger domain for antibody reactivity indicates that
antibodies against VtaA10 are mostly directed
against conformational epitopes, which can be
partially recovered after denaturation. Further-
more, it seems that the complete passenger
domain has a greater resistance to denaturation
and is better recognized by the antibodies. In
other bacterial species, AT-2 like NadA are
known to maintain secondary and tertiary
structure after denaturation conditions [5, 14].
However, convalescent sera from patients with
meningitis react against the NadA passen-
ger domains and all sub-fragments derived
from it [13].
No serological IgA response was detected
against the VtaA of the Nagasaki strain albeit
with only one exception. With the human respi-
ratory pathogen Moraxella catarrhalis, a muco-
sal IgA and a serological IgG response against
AT-2 (UspA or Hag) can be detected in conva-
lescent sera, and both responses correlate with
clearance of pathogenic strains [17, 22, 23].
In contrast, with the human systemic pathogen
Neisseria meningitidis, NadA induces only IgG
responses [13]. Interestingly, the H. parasuis
Nagasaki strain is also highly invasive and
vtaA antigenicity Vet. Res. (2010) 41:26
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lung only for a short period of time after exper-
imental inoculation [32]. Further studies will
be necessary to establish a protective role for
antibodies against VtaA.
In conclusion, these results show the pro-
duction of an IgG response against VtaA in
piglets infected with H. parasuis, indicating
that they are expressed in vivo and might play
a role in the interaction between the host and
pathogen in animals exposed to the bacteria.
Accordingly, they could be good candidates
to be used as immunogens for vaccine develop-
ment. However, whether this IgG response
against the VtaA confers protection against
H. parasuis infection and Gla ¨sser’s disease
onset has to be further studied.
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